Relmada Therapeutics, Inc. (RLMD) Reports 91% Response Rate in Phase 2 Bladder Cancer Study
Relmada Therapeutics, Inc. (NASDAQ:RLMD) is a clinical-stage biotechnology company developing therapies for central nervous system disorders and oncology.
Relmada Therapeutics Inc. (RLMD)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Driehaus Capital Richard Driehaus | 740,006 | $444,226 | 0% | |
| 2. | Marshall Wace LLP Paul Marshall And Ian Wace | 154,568 | $92,741 | 0% | |
| 3. | Renaissance Technologies Jim Simons | 150,100 | $90,105 | +21% | 0% |
| 4. | ADAR1 Capital Management Daniel Schneeberger | 130,000 | $78,039 | 0.01% | |
| 5. | LMR Partners Ben Levine, Andrew Manuel And Stefan Renold | 55,104 | $33,079 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.74 | 55,976 | $41,422.24 | 1,000,000 | 2025-08-28 | Filing | |
| $0.67 | 129,455 | $86,734.85 | 944,024 | 2025-08-27 | Filing | |
| $0.62 | 80,545 | $49,937.90 | 814,569 | 2025-08-26 | Filing | |
| $0.43 | 200,000 | $86,060.00 | 412,295 | 2025-05-16 | Filing | |
| $0.52 | 60,000 | $31,422.00 | 288,335 | 2025-05-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.32 | 4,068 | $74,525.76 | 88,774 | 2022-07-01 | Filing | |
| $18.45 | 8,848 | $163,245.60 | 92,842 | 2022-07-01 | Filing | |
| $18.48 | 839 | $15,504.72 | 101,690 | 2022-07-01 | Filing | |
| $19.01 | 10,698 | $203,368.98 | 88,774 | 2022-06-30 | Filing | |
| $19.37 | 5,314 | $102,932.18 | 99,472 | 2022-06-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 508,000 | $304,952 | 0% | |
| 2. | 396,514 | $238,027 | 0.04% | |
| 3. | 364,077 | $218,446 | 0% | |
| 4. | 302,354 | $181,541 | 0% | |
| 5. | 224,846 | $134,908 | 0% |
News See All
13 Best Psychedelic Stocks to Invest in Now
Unlike drugs such as cocaine or marijuana, psychedelics create an “alternate reality” by altering feelings, thoughts, and energy levels.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Relmada Therapeutics Second Quarter 2025 Earnings Conference Call.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call Transcript
Operator: Good afternoon. Welcome to the Relmada Therapeutics First Quarter 2025 Earnings Call.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Relmada Therapeutics, Incorporated Quarter 4 2024 Financial Results Call. At this time, all participants are in a listen-only mode.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2024 Earnings Call Transcript
Operator: Hello and welcome to the Relmada Therapeutics Third Quarter 2024 Earnings Conference Call.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q2 2024 Earnings Call Transcript
Operator: Good afternoon. Welcome to the Relmada Therapeutics Inc.'s Second Quarter 2024 Earnings Conference Call. At this time, all lines are in a listen-only mode.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Relmada Therapeutics Inc. First Quarter 2024 Financial Results Conference Call. At this time, all lines are in a listen-only mode.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript
Relmada Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.84, expectations were $-0.88.
11 Best Psychedelic Stocks to Buy in 2024
Unlike substances like marijuana or cocaine, psychedelics are potent and serve as a form of gateway to an 'alternate reality' for those who use them.
Hedge Fund Resource Center Billionaire Hedge Funds
